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Structure of TAR RNA Complexed
with a Tat-TAR Interaction Nanomolar Inhibitor
that Was Identified by Computational Screening
1A for a secondary-structure diagram of HIV-1 TAR) in
solution. The 5 bulge is the same region previously
identified as the site of Tat binding [5–7]. We have also
shown via electrophoretic mobility shift assays that
these TAR ligands, at concentrations between 0.1 and
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1 M, disrupt the Tat-TAR interaction in vitro [1]. In
the current paper, we present the high-resolution NMR
structure of TAR in complex with acetylpromazine (alsoSummary
known as acetopromazine or acepromazine; see Figure
1B for the chemical structure). At a concentration of 100HIV-1 TAR RNA functions critically in viral replication
by binding the transactivating regulatory protein Tat. nM, acetylpromazine completely inhibited the interac-
tion of TAR and Tat, both at 100 nM. While the acetylpro-We recently identified several compounds that experi-
mentally inhibit the Tat-TAR interaction completely at mazine-TAR structure is largely consistent with that pre-
dicted in our computational screen, the experimentallya 100 nM concentration. We used computational
screening of the 181,000-compound Available Chemi- determined structure shows that the conformation of
the target TAR is modified somewhat upon complexcals Directory against the three-dimensional structure
of TAR [1]. Here we report the NMR-derived structure formation. Using the structure of the complex, we can
suggest ways likely to improve binding affinity and spec-of TAR complexed with acetylpromazine. This struc-
ture represents a new class of compounds with good ificity in the next cycle of drug design and development
in particular and to provide insights into RNA structure-bioavailability and low toxicity that bind with high affin-
ity to TAR. NMR data unambiguously show that acetyl- based drug discovery in general.
promazine binds only to the unique 5 bulge site to
which the Tat protein binds. Specificity and affinity of
Results and Discussionbinding are conferred primarily by a network of base
stacking and hydrophobic interactions. Acetylproma-
Specific Binding of Acetylpromazine to the TARzine alters the structure of free TAR less than Tat
Internal Bulgepeptides and neomycin do.
One-dimensional imino proton spectra in Figure 2A
show selective changes in chemical shifts as acetylpro-Introduction
mazine is added to free TAR and confirm that a 1:1
complex is formed. Some of the signals are broadenedThe past decade has witnessed rapid progress in the
more than one would expect from the gain in size, im-structure determination of biologically important RNA
plying that complex formation occurs in the intermediatemolecules via X-ray crystallography and NMR. The newly
exchange regime of the NMR time scale.available structural information not only provides valuable
Within HIV-1 TAR, the Tat binding site comprises theinsights into how RNA molecules function in living cells but
5 bulge with three pyrimidine residues, U23, C24, andalso opens the avenue for discovery of RNA-targeting
U25 (Figure 1A), and their adjacent base-pairs. Becausetherapeutic agents based on the detailed three-dimen-
these and other pyrimidine residues yield distinctive H5-sional structure. We have demonstrated the feasibility
H6 crosspeaks in a 2D TOCSY spectrum, we have beenof our structure-based computational screening strat-
able to use homonuclear 2D TOCSY experiments toegy for drug discovery. We have identified several small-
identify compounds that bind to the 5 bulge by examin-molecular-weight organic compounds that bind HIV-1
ing chemical-shift changes in the H5-H6 region [1]. WeTAR and completely inhibit, at concentrations of 100 nM,
have shown that upon addition of acetylpromazine, onlyits interaction with equimolar HIV-1 Tat protein [1, 2].
those pyrimidine residues in the bulge region (U23, C24,The TAR-Tat protein interaction is essential for HIV repli-
U25, C39, and U40) exhibited noticeable chemical-shiftcation because the binding of Tat to TAR is required for
changes, whereas other pyrimidine residues were notactivating transcription of the HIV genome [3, 4]. Finding
affected. This dramatic result provided the first line oftherapeutic agents that disrupt the Tat-TAR interaction
NMR evidence indicating that acetylpromazine inter-therefore would provide a strategy for inhibiting HIV repli-
acted with TAR specifically in the bulge region. Subse-cation. Based on an NMR-derived structural model of HIV-1
quent heteronuclear NMR experiments performed onTAR, we have performed computational virtual screening
various labeled TAR samples confirmed that all of theof the approximately 153,000–181,000 compounds in
observed chemical-shift changes induced by acetylpro-the Available Chemicals Directory (ACD) [1, 2]. Using NMR
mazine were confined to residues within or around theas an experimental screening tool, we have verified that
5 bulge (reference [1] and Figures 2B–2D herein). Nu-some of the top-scoring compounds identified via virtual
merous spectral assignments for TAR, both free and inscreening actually bind to the 5bulge of TAR (see Figure
the presence of acetylpromazine at a ratio of 2:1, en-
abled us to readily identify the following substantial1Correspondence: james@picasso.ucsf.edu
(0.1 ppm) proton chemical-shift changes (downfield2 Present Address: Structural GenomiX, 525 Brannan St., Suite 200,
San Francisco, CA 94107. and upfield shifts are denoted by positive and negative
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Experimental Procedures. Structure refinement statis-
tics are summarized in Table 2. Because of the large
number of intermolecular NOEs, 51, between acetylpro-
mazine and TAR (Figure 3B), binding of acetylpromazine
to the 5 bulge is very well defined. Figure 4A shows
twelve superimposed refined structures of the complex.
Except for the poorly defined loop nucleotides (C30–
A35), the structures superimpose very well. In Figure
4B, a representative structure is shown, with a ribbon
representing the RNA backbone. Two views of the inter-
nal bulge region are shown in Figure 5. U23, U25, and
benzene ring II of acetylpromazine are placed along the
major groove, whereas benzene ring I and the aliphatic
moiety of acetylpromazine, together with C24, lie along
the minor groove.
The three-member ring of acetylpromazine inserts be-
tween base pairs G26-C39 and A22-U40, preventing
continuous stacking of the lower and upper stems as
observed in structures induced by argininamide or Tat-
Figure 1. HIV-1 TAR RNA and Acetylpromazine peptide [8–10]. However, another set of base-stacking
(A) Sequence and numbering system of the 31 nucleotide HIV-1 TAR interactions is created. U23 continues stacking on A22
construct used in this study. in the fashion of an A helix. This is evident by the NOEs
(B) Chemical structure and numbering system of acetylpromazine. from U23 H6 to A22 H2 and H3 as well as from U23
H1 to A22 H2. Benzene ring II of acetylpromazine is
values, in ppm, respectively): A22H8 (0.12), A22H3 stacked on U40. Stacking of U23 on A22 and benzene
(0.14), U23H6 (0.16), U23H5 (0.22), U23H1 (0.14), ring II on U40 arranges the U23 base and benzene ring
U23H2 (0.13), U23H4 (0.15), C24H1 (0.10), II such that they look like an extra base pair continuing
U25H2 (0.11), U25H3 (0.17), G26H1 (0.22), helical stacking on the A22–U40 base pair. This “pseudo
C39H1 (0.13), C39H3 (0.15), U40H6 (0.11), U40H5 base pair” may contribute to the creation of a deeper
(0.10), U40H1 (0.18), C41H6 (0.12), C41H5 (0.13). minor groove (compared to that of the standard A helix)
All of these chemical-shift changes are observed for to accommodate the aliphatic moiety of acetylproma-
nuclei that belong to the three bulged residues U23, zine. On the major-groove side, U25 stacks on benzene
C24, U25 and adjacent base pairs (A22, G26, C39, U40, ring II of acetylpromazine. Figure 5B illustrates that ben-
and C41). Even in the presence of a 5-fold excess of zene ring II is “sandwiched” between the U25 and U40
acetylpromazine, no noticeable chemical-shift change bases. Benzene ring I, which forms an angle of about
was detected from nuclei that belong to residues in 135 with benzene ring II, is positioned below G26. Par-
other regions of TAR. These chemical-shift observations tial stacking of G26 and benzene ring I is possible.
demonstrate that binding of acetylpromazine to TAR is The aliphatic moiety of acetylpromazine is extended
specific to the bulge region. Nonspecific ligand-RNA along the minor groove. NOEs from the H protons of
interactions do not seem to play any role in the interac- acetylpromazine to C41 H5 and H1 protons are ob-
tion between acetylpromazine and TAR. served, indicating that the tail of the aliphatic chain is
Besides gathering chemical-shift change data, we in close proximity to the G21-C41 base pair. Also in the
also identified a large number of intermolecular NOEs minor groove, C24 has its base moiety close to the A22-
between acetylpromazine and TAR. For example, Figure U40 and G21-C41 base pairs. C24 helps to bury the
3A shows several NOEs between the U40 H1 proton aliphatic chain of acetylpromazine within the minor
and acetylpromazine protons in a 3D 13C-edited NOESY- groove (Figure 5C).
HMQC experiment performed on an RNA sample with
only the U residues labeled. Acetylpromazine protons
resonate in regions (1.90–3.50 and 6.45–6.95 ppm for Comparison with Other TAR Structures
Several TAR structures have been reported previously,aliphatic and aromatic protons, respectively) distinct
from those of RNA protons, greatly facilitating identifica- including a number of NMR structures of free TAR and
TAR in the presence of argininamide or Tat-peptide [8–10],tion of intermolecular NOEs between acetylpromazine
and TAR. The 51 intermolecular NOEs are shown graphi- an NMR structure of TAR in complex with neomycin B
[11], and a crystal structure of the TAR bulge regioncally in Figure 3B and are listed in Table 1. In accord with
the chemical-shift data, all RNA resonances involved in stabilized by several calcium ions [12]. Free TAR in solu-
tion was shown to have U23 stacked on A22, causingintermolecular NOEs are from nuclei in the bulge and
flanking base pairs, providing another strong piece of helical bending of the molecule. Binding of argininamide,
Tat-peptide, or neomycin B to TAR causes conforma-NMR evidence for the very specific binding of acetylpro-
mazine to the bulge region of TAR. tional changes around the bulge region. In all cases,
stacking of U23 on A22 is disrupted, and A22-U40 and
G26-C39 base pairs are more or less stacked, resultingStructure of the Acetylpromazine-TAR Complex
The solution structure of the acetylpromazine-TAR com- in a continuous helix in the RNA stem. Positions of the
bulge residues are varied. In argininamide or Tat-peptideplex was determined with the protocol described in the
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Figure 2. Chemical-Shift Changes of TAR
upon Acetylpromazine Binding
(A) 1D imino proton spectra of TAR RNA in
the absence and presence of acetylproma-
zine, as follows: (bottom) free TAR RNA, (mid-
dle) TAR-to-acetylpromazine molar ratio of
nearly 1 to 1, and (top) TAR-to-acetylproma-
zine molar ratio of about 1 to 2. The spectra
were collected at 10C. The sample contained
about 2 mM TAR RNA in 10 mM sodium phos-
phate (pH 6.5) and 20 mM NaCl. For the 2D
NMR spectra, crosspeaks from the free TAR
and TAR-acetylpromazine complex are col-
ored red and blue, respectively. Black arrows
indicate notable chemical-shift changes.
(B) 2D HCCH-COSY spectra showing H1-to-
H2 crosspeaks of a TAR sample with all cyto-
sine residues isotopically labeled.
(C,D) 1H13C-HSQC spectra of the aromatic and
ribose moieties of a TAR sample with all ade-
nine residues isotopically labeled.
bound structures, U23 is in the major groove, C24 is plex, the minor groove is not solely defined by the RNA.
Instead, benzene ring II is actively involved.exposed to solvent, and U25 is on the minor groove
side; in the neomycin bound conformation, U23 and C24
are both positioned in the minor groove side, and U25 Significance
protrudes out of the helix. Whereas binding of argini-
namide or Tat-peptide occurs on the major groove side, The acetylpromazine-TAR structure reported here is
significant in several respects. First, it justifies the RNAbinding of neomycin B is in the minor groove. Clearly,
the acetylpromazine bound structure we present here structure-based computational screening procedure
we have developed. Second, it suggests possible waysdiffers from all of the reported TAR structures. Unlike
other ligand-induced structures, U23 still stacks on A22 to improve binding specificity and affinity in designing
next-generation compounds. Third, our structure clearlyin our structure, which is very similar to free TAR in
solution. It was reported that unstacking of U23 on A22 differs from the Tat-peptide or argininamide-com-
plexed TAR, suggesting that some variability in thecaused a very large upfield shift (0.5 ppm) of A22 H2
proton [8–10]. With acetylpromazine, the chemical shift structure of the RNA target may be tolerated. It re-
mains for us to test the extent of initial structure vari-of the A22 H2 proton is virtually unchanged (Figure 2C);
-helical-like interresidue NOEs were observed between ability that can be tolerated. However, ligands capable
of locking TAR into a stable conformation, regardlessU23 and A22. In the acetylpromazine bound structure,
stacking between upper and lower stems becomes im- of similarity to the Tat bound conformation, should
prove useful in combating HIV-1 infection. RNA is typi-possible because of insertion of the three-member ring
from the ligand. However, insertion of acetylpromazine cally flexible and adopts rather different conforma-
tions upon the binding of different ligands. The acetyl-benzene ring II between U40 and U25 creates a continu-
ous stack of ten bases (including benzene ring II) involv- promazine-TAR structure not only corroborates this
observation but also has fascinating implications foring the non-bulge strand (U40–C46), the ligand, and
bulge residue U25. Similar to neomycin B binding, ben- RNA structure-based drug discovery. The discrepancy
between the acetylpromazine-induced structure andzene ring I and the aliphatic tail of acetylpromazine are
aligned along the minor groove. However, in our com- the Tat-induced structure argues for the feasibility of
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Figure 3. Examples of Intermolecular NOEs
between TAR and Acetylpromazine
(A) Shown is a slice at the U40 C1 chemical
shift taken from a 13C-edited 3D NOESY-
HMQC spectrum (300 ms mixing time) of a
TAR sample with all uracil residues isotopi-
cally labeled. Note that the intermolecular
NOEs are unambiguously identified because
acetylpromazine protons resonate within dis-
tinctive chemical-shift ranges without over-
lapping TAR resonances.
(B) A graphical representation of the 51 inter-
molecular NOEs that define the interaction
between TAR and acetylpromazine. See text
for a full list of these NOEs. The coloring
schemes are: G21-C41 and A27-U38 base
pairs (green), A22-U40 base pair (blue), G26-
C39 base pair (gold), U23 (yellow), C24 (cyan),
U25 (magenta), and acetylpromazine (red).
Each NOE is represented as a thinner green
bar connecting the two protons involved.
Experimental Proceduresembarking on a program of structure-based lead com-
pound discovery against a pathogenic RNA even when
Sample Preparationthe conformation of the RNA in complex with its bio-
Five different samples of the 31 nucleotide TAR were prepared:
logically relevant partner has not been determined. unlabeled, uniformly 13C,15N-labeled, and type-specifically
This is important because determining the structure 13C,15N-labeled at G, A, or C residues, respectively. All samples were
prepared by in vitro transcription with T7 RNA polymerase and aof a disease-related RNA molecule can be slow, and
synthetic DNA template [13] and purified as described [14]. Acetyl-some RNA molecules are refractory to structure deter-
promazine was purchased from Research Diagnostics. Final samplemination approaches. Finally, although several struc-
conditions were 1–2 mM RNA in 10 mM sodium phosphate buffertures of RNA in complex with small-molecular-weight
(pH 6.5) and 20 mM sodium chloride. Acetylpromazine was added
ligands have been reported, most of these RNA bind- in about 2-fold excess over RNA.
ing ligands fall into one of three categories: amino acid
or peptide analog, nucleoside analog, or aminoglyco- NMR Spectroscopy
All NMR experiments were performed on Varian Inova 600 MHzside. The structure of the acetylpromazine-TAR com-
spectrometers. Spectra were processed with NMRpipe [15] andplex therefore provides new insights into principles of
analyzed with SPARKY [16]. Homonuclear 2D NOESY spectra inRNA recognition by small organic compounds. The
H2O were collected at 10C with the SSNOESY pulse sequence [17].compounds we identified as specific TAR binders may Homonuclear 2D NOESY, DQF-COSY, and TOCSY spectra in D2O
provide a new scaffold for development of novel RNA were recorded at 25C and 35C. The NOESY spectra were recorded
with mixing times of 50, 100, 200, and 300 ms to monitor the NOEbinding therapeutic agents.
Table 1. Intermolecular NOEs between TAR and Acetylpromazine
Actylpromazine Proton TAR Proton
H1 G26H1(w), U40H1(m), U40H2(w)
H3 G26H1(vw), U40H1(w), U40H4(m)
H4 G26H1(vw), C39H2(m), U40H1(vw), U40H1(w), U40H6(w)
H8 C39H2(w), C39H5(w), C39H6(w), U40H1(vw), U40H6(m)
H9 U40H1(vw), U40H6(m)
H10/H11 U25H2(vw), U25H6(w), U40H1(s), U40H2(w)
H U25H2(m), U25H6(w), G26H1(w), U40H1(m)
H1	 C24H2(vw), U25H2(w), U25H6(vw), U40H1(s), U40H2(w)
H
 U25H6(m), U40H1(m), U40H2(w), U40H6(vw)
H A22H1(w), A22H2(vw), U23H1(m), C24H1(w), C24H2(m), U25H2(w), U25H5(w),
U25H6(w), U40H1(s), U40H2(m), U40H6(w), C41H1(w), C41H5(w)
H2	 G26H1 (vw), U40H1 (w), U40H2 (w)
s: strong; m: medium; w: weak; vw: very weak.
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Table 2. Restraint and Structure Statistics
A. Distance and dihedral restraints
Intranucleotide NOEs 378
Sequential NOEs 179
Medium/long-range NOEs 57
Intermolecular NOEs 51
Total number of NOEs 665
Hydrogen bond restraints 60
Dihedral restraints for sugar puckers 90
Total number of NMR restraints 815
Mean number per residue 25.5
B. Superposition of 12 structures (pairwise rmsd)
All nucleotides and ACP (A˚) 3.17
16–29, 36–46, ACP (A˚) 1.23
21–27, 38–41, ACP (A˚) 0.82
crosspeak intensity build-ups. One bond-correlated 1H-15N HMQC
spectra were obtained at 10C in H2O. All heteronuclear experiments Figure 5. Views of the Bulge Region of the TAR-Acetylpromazine
in D2O were performed at 35C. One-bond 1H-13C correlations were Complex
obtained with constant-time HSQC. Adenine H2 proton-to-H8 pro-
(A) From the minor groove.
ton long-range correlations were established by a 2D HCCH-TOCSY
(B) From the major groove (180 rotation from [A]).
experiment. Ribose spin systems were identified by 3D 13C-edited
(C) Space-filling representation with the same view as (A). The color
HCCH-COSY and 3D HCCH-TOCSY experiments [18]. Correlations
scheme is identical to that in Figure 3B except that the aromatic
of base and ribose protons were established by 2D HCN experi-
moiety (including the acetyl group) of acetylpromazine is colored
ments. 3D 13C-edited NOESY-HMQC spectra optimized for observa-
darker to distinguish it from the aliphatic moiety, which is embedded
tion of either base or sugar moieties were recorded with a mixing
in the minor groove.
time of 150 ms. 2D 13C-edited NOESY spectra were collected on
the type-specific labeled samples.
build-up series and the 3D 13C-edited NOESY spectra and wereNMR-Derived Restraints
assigned to four categories, as follows: strong (1.8–3.0 A˚), mediumInterproton distance restraints between nonexchangeable protons
(1.8–4.0 A˚), weak (1.8–5.0 A˚), and very weak (1.8–6.0 A˚). Distancewere obtained from the intensities of crosspeaks in the 2D NOE
restraints involving exchangeable protons were assigned to two
categories with upper bounds of 4.0 or 6.0 A˚, respectively. The very
strong NOEs from adenine-H2 to uridine-NH and from cytosine-NH2
to guanosine-NH within Watson-Crick base pairs were assigned an
upper bound of 4.0 A˚. All other NOEs in water were assigned an
upper bound of 6.0 A˚. No intramolecular NOEs within acetylproma-
zine were used as distance restraints. Hydrogen bond restraints
were only imposed on base pairs established by the observation of
imino proton resonances and internucleotide NOEs characteristic
of base pair formation. These restraints were based on standard
base pair geometry of nucleic acids [19] and were given a range
of 0.2 A˚. Torsion angle restraints for ribose sugar conformation
were based on analysis of the 2D DQF-COSY spectra. Sugars show-
ing a strong H1-H2 crosspeak were restrained to C2-endo. Those
with no COSY and TOCSY crosspeaks were interpreted as C3-
endo. All other nucleotides were left unconstrained.
Structure Determination
Structure refinement was performed with the programs DYANA 1.6
[20] and AMBER 6.0 [21, 22]. DYANA was used to generate 200
random initial structures subject them to simulated annealing in
torsion angle space. This was followed by variable target function
minimization. The twenty DYANA structures with the lowest target
function values and correct chirality (checked with the program
CHIRANO, developed by N. Ulyanov at the University of California,
San Francisco) were chosen for further refinement via restrained
Figure 4. Structures of TAR in Complex with Acetylpromazine molecular dynamics with AMBER. The 12 structures with the lowest
AMBER energy were chosen to represent the final structure ensem-(A) Superposition of the eleven refined structures of the TAR-acetyl-
ble, and these were analyzed with the program CARNAL [21]. Allpromazine complex. The superposition is performed on all residues
graphical figures were generated with MidasPlus [23].(including acetylpromazine) of the complex except the poorly de-
fined loop nucleotides (C30–A35). The coloring schemes for residues
G21–A27, U38–C41, and acetylpromazine are identical to that in Acknowledgments
Figure 3B. All other residues are colored black.
(B) One representative structure of the TAR-acetylpromazine com- This work was supported by grant AI46967 from the National Insti-
tutes of Health. We wish to thank Dr. James R. Williamson for gener-plex is shown with color ramping from the 5 end (red) to the 3 end
(blue) of TAR and with acetylpromazine highlighted in red. The ribbon ously giving us the assignments of free TAR and Dr. Nikolai Ulyanov
for assistance in using DYANA. We acknowledge use of the Univer-traces the backbone of TAR.
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